It is recommended to optimize the review and approval mechanism of biomedicine in Chengdu and Chongqing, and further promote the collection of non-immunization program vaccines
March 7, 2025
Source: drugdu
34
Jiang Lingfeng, deputy to the National People's Congress and vice chairman and president of Zhifei Bio, submitted several suggestions on the biomedicine industry at this National People's Congress. Among them, in order to "promote the high-quality development of the biomedicine industry in the Chengdu-Chongqing Twin Cities Economic Circle", Jiang Lingfeng suggested optimizing the review and approval mechanism of biomedicine in Chengdu and Chongqing, increasing policy support, and at the same time, providing more support in talent cultivation and introduction, and innovation resource allocation. In order to "further promote the collection of non-immunization program vaccines and promote the healthy and sustainable development of the vaccine industry", Jiang Lingfeng suggested resolving historical arrears through special debts, optimizing the disease control payment system, and building a new "special fund direct payment" mechanism to effectively alleviate the financial pressure of enterprises.
https://finance.eastmoney.com/a/202503053337321863.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Focusing on critical illness, Mindray Biotech and Likang Biomedical have reached a strategic cooperation March 7, 2025
- Zhao Jing, Vice Chairman of Buchang Pharmaceutical, made suggestions on AI empowering traditional Chinese medicine at the two sessions March 7, 2025
- It is recommended to optimize the construction of the centralized procurement system for biopharmaceuticals and support the high-quality development of enterprises March 7, 2025
- Breakthrough in Nobel Prize level base modification technology, Aibo Bio freeze-dried mRNA vaccine approved for clinical use | Yingke Family March 6, 2025
- Single product sells over 1 billion in China, hidden leader lays off 10% of employees March 6, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
